— Know what they know.
Not Investment Advice

DCPH NASDAQ

Deciphera Pharmaceuticals, Inc.
1W: +0.1% 1M: +0.9% 3M: +59.0% 1Y: +82.5% 3Y: -24.4% 5Y: +18.7%
$25.59
Last traded 2024-06-11 — delisted
NASDAQ · Healthcare · Drug Manufacturers - Specialty & Generic · $2.2B mcap · 46M float · 4.13% daily turnover

Balance Sheet Trends

Total Assets
$474M +4.3% ▲
5Y CAGR: +8.5%
Total Liabilities
$123M +9.2% ▲
5Y CAGR: +28.1%
Shareholders Equity
$351M +2.7% ▲
5Y CAGR: +4.6%
Cash & Investments
$306M -5.6% ▼
5Y CAGR: +0.8%
Total Debt
$26M -11.1% ▼
5Y CAGR: +15.4%
Net Debt
-$58M -61.8% ▼

Assets vs Liabilities & Equity

Year-over-Year Growth

View Full Balance Sheet
Line ItemFY2019FY2020FY2021FY2022FY2023
— Assets —
Cash$120M$136M$87M$65M$84M
Short-Term Investments$459M$416M$199M$260M$223M
Cash & ST Investments$580M$552M$286M$324M$306M
Net Receivables$0$14M$21M$22M$32M
Inventory$0$6M$14M$21M$21M
Other Current Assets$14M$12M$19M$25M$22M
Total Current Assets$593M$584M$339M$393M$381M
Property, Plant & Equip.$27M$46M$45M$43M$37M
Goodwill & Intangibles$0$0$0$0$0
Long-Term Investments$2M$9M$42M$15M$47M
Other Non-Current Assets$0$3M$3M$3M$8M
Total Non-Current Assets$29M$58M$90M$61M$92M
Total Assets$622M$642M$429M$454M$474M
— Liabilities —
Accounts Payable$20M$12M$13M$19M$26M
Short-Term Debt$2M$2M$3M$3M$4M
Deferred Revenue$0$0$80M$0$68M
Other Current Liabilities$39M$55M$1M$65M$2M
Total Current Liabilities$60M$70M$97M$86M$100M
Long-Term Debt$16M$29M$28M$26M$22M
Other Non-Current Liab.$0$0$0$0$0
Total Non-Current Liabilities$16M$29M$28M$26M$22M
Total Liabilities$76M$99M$125M$112M$123M
— Equity —
Common Stock$516K$576K$585K$676K$805K
Retained Earnings-$488M-$754M-$1.1B-$1.2B-$1.4B
Accumulated OCI$111K$11K$51K-$983K$577K
Total Stockholders Equity$546M$544M$305M$342M$351M
Total Liabilities & Equity$622M$642M$429M$454M$474M
— Key Metrics —
Total Debt$18M$31M$31M$29M$26M
Net Debt-$103M-$105M-$56M-$36M-$58M
Total Investments$461M$425M$241M$274M$269M

Sign in to InsiderStreet

You'll also get our free weekly newsletter with
smart money signals, market insights, and alpha ideas.
Unsubscribe anytime.

For informational purposes only. Not investment advice. Data sourced from SEC filings. Privacy Terms